{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:20:51Z","timestamp":1783056051567,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03270-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:34:40Z","timestamp":1774694080000},"page":"1118-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bleeding events in Asian patients with cancer-associated thrombosis: a 10-year single-centre experience"],"prefix":"10.1007","volume":"59","author":[{"given":"Helma","family":"Azmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Rafeah","family":"Tumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yew Sheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"4","key":"3270_CR1","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3390\/ijms24043169","volume":"24","author":"D Pastori","year":"2023","unstructured":"Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A et al (2023) A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci 24(4):3169. https:\/\/doi.org\/10.3390\/ijms24043169","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"3270_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/07357900802656681","volume":"27","author":"T Wun","year":"2009","unstructured":"Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Investig 27(Suppl 1):63\u201374. https:\/\/doi.org\/10.1080\/07357900802656681","journal-title":"Cancer Investig"},{"issue":"1","key":"3270_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12959-025-00710-2","volume":"23","author":"L Abbas","year":"2025","unstructured":"Abbas L, Muhamad Nor I, Ismail F, Palaniappan S, Chong GY, Wan Puteh SE, Muhamad Jamil SA, Tumian NR (2025) Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia. Thromb J 23(1):25. https:\/\/doi.org\/10.1186\/s12959-025-00710-2PMID: 40087785; PMCID: PMC11909829","journal-title":"Thromb J"},{"key":"3270_CR4","unstructured":"National Comprehensive Cancer Network (NCCN) (2025) Cancer-associated thromboembolic disease. Version 1.2025. Plymouth Meeting (PA): NCCN. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail\/cancer-associated-thromboembolic-disease"},{"issue":"25","key":"3270_CR5","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Mellemkj\u00e6r L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846\u20131850. https:\/\/doi.org\/10.1056\/NEJM200012213432504","journal-title":"N Engl J Med"},{"issue":"25","key":"3270_CR6","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1182\/bloodadvances.2021005725","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(25):5437\u20135470. https:\/\/doi.org\/10.1182\/bloodadvances.2021005725","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"3270_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/00325481.2021.1955542","volume":"133","author":"EJ Brea","year":"2021","unstructured":"Brea EJ, Tiu BC, Connors JM (2021) A comprehensive review of DOACs for cancer-associated VTE prophylaxis or treatment. Postgrad Med 133(Suppl 1):71\u201379. https:\/\/doi.org\/10.1080\/00325481.2021.1955542","journal-title":"Postgrad Med"},{"issue":"3","key":"3270_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11239-020-02055-1","volume":"50","author":"V Mai","year":"2020","unstructured":"Mai V, Tanguay VF, Guay CA, Bertoletti L, Magnan S, Turgeon AF et al (2020) DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. J Thromb Thrombolysis 50(3):661\u2013667. https:\/\/doi.org\/10.1007\/s11239-020-02055-1","journal-title":"J Thromb Thrombolysis"},{"issue":"20","key":"3270_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","journal-title":"J Clin Oncol"},{"issue":"7","key":"3270_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"14","key":"3270_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ajhp\/zxz095","volume":"76","author":"JB Bossaer","year":"2019","unstructured":"Bossaer JB, Covert KL (2019) Direct oral anticoagulants in patients with cancer. Am J Health Syst Pharm 76(14):1019\u20131027. https:\/\/doi.org\/10.1093\/ajhp\/zxz095","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"3270_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"issue":"17","key":"3270_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"key":"3270_CR14","doi-asserted-by":"publisher","first-page":"1132156","DOI":"10.3389\/fcvm.2023.1132156","volume":"10","author":"G Po\u00e9nou","year":"2023","unstructured":"Po\u00e9nou G, Tol\u00e9dano E, Helfer H, Plaisance L, Happe F, Versini E, Diab N, Djennaoui S, Mah\u00e9 I (2023) Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events. Front Cardiovasc Med 10:1132156. https:\/\/doi.org\/10.3389\/fcvm.2023.1132156","journal-title":"Front Cardiovasc Med"},{"key":"3270_CR15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1782219","author":"Z Zaboras","year":"2024","unstructured":"Zaboras Z, J\u00f8rgensen CT, Stensvold A, Pettersen HH, Galovic Grdinic A, Br\u00e6kkan SK et al (2024) TH Open 8(1):e132\u2013e140. https:\/\/doi.org\/10.1055\/s-0044-1782219. Real-world data on treatment patterns and bleeding in cancer-associated thrombosis: Data from the TROLL Registry"},{"issue":"9","key":"3270_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O\u2019Connell C et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891\u20131894","journal-title":"J Thromb Haemost"},{"key":"3270_CR17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS et al (2023) Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 41:3063\u20133071","journal-title":"J Clin Oncol"},{"issue":"37","key":"3270_CR18","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1093\/eurheartj\/ehad123","volume":"44","author":"European Society of Cardiology","year":"2023","unstructured":"European Society of Cardiology (2023) ESC guidelines on the treatment and prevention of venous thromboembolism in cancer. Eur Heart J 44(37):3778\u20133815. https:\/\/doi.org\/10.1093\/eurheartj\/ehad123","journal-title":"Eur Heart J"},{"issue":"1135","key":"3270_CR19","doi-asserted-by":"publisher","first-page":"20211158","DOI":"10.1259\/bjr.20211158","volume":"95","author":"MX Wang","year":"2022","unstructured":"Wang MX, Guccione J, Korivi BR, Abdelsalam ME, Klimkowski SP, Soliman M et al (2022) Gastrointestinal bleeding: imaging and interventions in cancer patients. Br J Radiol 95(1135):20211158","journal-title":"Br J Radiol"},{"issue":"9 Suppl","key":"3270_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.20162","volume":"100","author":"ST Sonis","year":"2004","unstructured":"Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995\u20132025","journal-title":"Cancer"},{"issue":"1","key":"3270_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/asheducation-2017.1.128","volume":"2017","author":"AA Khorana","year":"2017","unstructured":"Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O\u2019Connell C et al (2017) When can we stop anticoagulation in patients with cancer-associated thrombosis? Hematol Am Soc Hematol Educ Program 2017(1):128\u2013135","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"3270_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11239-010-0438-8","volume":"30","author":"Z Kovac","year":"2010","unstructured":"Kovac Z, Kovac M, Mitic G, Antonijevic N (2010) The oncology treatment of patients who use oral anticoagulants is connected with high risk of bleeding complications. J Thromb Thrombolysis 30(2):210\u2013214. https:\/\/doi.org\/10.1007\/s11239-010-0438-8PMID:20082209","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3270_CR23","doi-asserted-by":"publisher","first-page":"030006051989443","DOI":"10.1177\/0300060519894439","volume":"48","author":"P Bhardwaj","year":"2020","unstructured":"Bhardwaj P, Petersen LB, Binko TS, Petersen JR, Fornitz GG (2020) Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants. J Int Med Res 48(6):0300060519894439. https:\/\/doi.org\/10.1177\/0300060519894439PMCID: PMC7294381","journal-title":"J Int Med Res"},{"issue":"11","key":"3270_CR24","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1253\/circj.CJ-20-0518","volume":"84","author":"Y Yamashita","year":"2020","unstructured":"Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K et al (2020) Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism: From the COMMAND VTE Registry. Circ J 84(11):2023\u20132031","journal-title":"Circ J"},{"issue":"5","key":"3270_CR25","first-page":"819","volume":"6","author":"J Trujillo-Santos","year":"2008","unstructured":"Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P et al (2008) Predicting recurrences or major bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 6(5):819\u2013825","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03270-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:01:19Z","timestamp":1783054879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03270-y","relation":{"references":[{"id-type":"doi","id":"10.1055\/s-0044-1782219","asserted-by":"subject"}]},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}